SOURCE: Symbollon Pharmaceuticals, Inc.

October 11, 2005 09:51 ET

Symbollon Pharmaceuticals, Inc. Announces Strategic Alliance With Premier Funding and Financial Marketing Services of Mesa, Arizona

FRAMINGHAM, MA -- (MARKET WIRE) -- October 11, 2005 -- Symbollon Pharmaceuticals, Inc. (OTC BB: SYMBA) announced today that it has established a strategic alliance with Premier Funding and Financial Marketing Services LLC of Mesa, Arizona. Premier will focus on corporate imaging and creating retail market awareness for the existing and new shareholder base.

Paul C. Desjourdy, President and Chief Executive Officer of Symbollon said, "We are pleased to be associated with a high-powered financial company of the caliber of Premier. We believe Premier will help bring investor awareness to our stock and brand awareness for our products to the financial community. We believe Premier will aggressively and successfully introduce our unique company to the public markets, broker dealer associations, financial services sector and institutional investors of public companies while enhancing our brand name awareness."

Kelly Black, President and CEO of Premier Funding and Financial Marketing Services, said, "We are proud to work with Symbollon Pharmaceuticals. We believe they have an innovative technology to help improve breast health and potentially prevent certain types of breast cancer." Ms. Black went on to state, "At Premier we look for companies to work with that are making dramatic changes in their market place and we are impressed with the high quality standards of and unique market opportunities for Symbollon Pharmaceuticals."

About: Symbollon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary drugs based on its molecular iodine technology. Symbollon has initiated a Phase III clinical trial evaluating IoGen as a potential treatment for moderate to severe cyclic pain and tenderness (clinical mastalgia) associated with fibrocystic breast disease (FBD). FBD is a condition that affects about 24 million women in the U.S., and there are approximately 7 million women suffering from clinical cyclic mastalgia. The Company believes IoGen also may be useful in treating and/or preventing endometriosis, ovarian cysts, and premenopausal breast cancer.

About: Premier Funding and Financial Marketing Services is the liaison to the investment community, finding the right financial support and solutions for the capital needs of publicly traded companies. Premier also is focused upon providing corporate imaging, public relations, financial marketing, and sales support.

Forward-Looking Statements: This news release contains statements by the Company that involve risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties associated with whether (i) future clinical trial results will support the use of IoGen for the treatment of fibrocystic breast disease, (ii) the clinical data acquired from Mimetix Inc. will be acceptable exposure data for IoGen, (iii) Symbollon will be able to obtain the resources necessary to complete the development process for IoGen and to continue its operations, (iv) IoGen will successfully complete the regulatory approval process, (v) competitive products will receive regulatory approval, (vi) the Company's ability to enter into new arrangements with corporate partners and (vii) such other factors as may be disclosed from time-to-time in the Company's reports as filed with the Securities and Exchange Commission. Given these uncertainties, current or prospective investors are cautioned not to place undue reliance on any such forward-looking statements.

Contact Information